Argenica Therapeutics Ltd has released a press release.
Preclinical HIE Study - ARG007 Effective Stand-Alone Therapy
Filed with ASX ·
6ix hasn’t read this filing yet.
Argenica Therapeutics Ltd on 6ix
Earlier from Argenica Therapeutics
- Ethics Approval Received for Phase 2 Trial
- Grant Awarded To Develop Additional Administration Route
- Positive FDA Feedback Following Pre-Ind Meeting
- Appendix 4E & Annual Report 30 June 2023
- Response to ASX Aware Query
Later from Argenica Therapeutics
- ARG-007 Inhibits Cause of Alzheimer's in Pre-Clinical Study
- Argenica Receives $2.09m R&D Tax Incentive Cash Rebate
- FDA Grants Orphan Drug Designation for ARG-007 HIE Treatment
- Appointment of Non-Executive Chair
- Phase 2 Manufacturing Completed & Trial Update
Follow Argenica Therapeutics into a list and get an email when it puts out news.
Follow Argenica Therapeutics